A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients

Massimiliano Lanzafame, Stefano Bonora, Emanuela Lattuada, Andrea Calcagno, Sandro Vento
2011 Brazilian Journal of Infectious Diseases  
Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIVpositive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replication
doi:10.1016/s1413-8670(11)70237-9 pmid:22230862 fatcat:rfzsjgjnezbbxczkoroezidhme